Rigel Pharmaceuticals, Inc. (RIGL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)

RIGL 37.87

+33.8%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	5/20/2008 12:29:31 PM
	of 566

looks like the R788 lymphoma presentation will be Thursday, June 8...... TAMATINIB FOSDIUM (TAMF), AN ORAL SYK INHIBITOR, HAS SIGNIFICANT CLINICAL ACTIVITY IN B-CELL NON-HODGKIN’S LYMPHOMA (NHL) J. Friedberg et al (Rochester, USA) lymphcon.ch (follow the links for scientific program and dl of final program)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next